• Go to navigation
  • Go to content
Welcome to Zomig.info!

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca
  • Zomig
  • Zomig Rapimelt
  • Zomig Nasal Spray

Main navigation

  • Home
  • Is it Migraine?
  • Learn About Migraine
  • Treating Migraine
  • Help For Your Migraine Patients
    • Migraine Patient Information Leaflets
    • Managing Your Migraine Booklet
    • Migraine Tips and Hints
    • Recipes that Eliminate Migraine Triggers
    • Migraine Disability Assessment (MIDAS) Questionnaire
    • Useful Links
    • Migraine Management Tools
    • Migraine Diary
  • Scientific Opinions
  • Learn about Zomig
  • eDetailing
  • Prescribing Information
  • Migraine Glossary and Useful Links
  • References
  • About AstraZeneca
  • Sitemap

You are here

  • Home
  • Help For Your Migraine Patients
  • Migraine Disability Assessment (MIDAS) Questionnaire

The Migraine Disability Assessment (MIDAS) questionnaire is a self-administered form that measures a patient’s headache-related disability. The questionnaire helps both patients and physicians improve the management of migraine. MIDAS can be used prior to and at the time of an initial consultation and throughout treatment to monitor the patient’s progress.

What does the MIDAS questionaire assess?
The MIDAS questionnaire assesses the impact that migraine has on a patient’s work and social life. Five questions assess the impact in terms of the number of days affected by migraine, while two further questions assess the severity of pain and the frequency of attacks. The patient is graded according to their responses as having minimal (grade I), mild (grade II), moderate (grade III) orsevere (grade IV) disability. This MIDAS grade, along with an understanding of the patient’s attack characteristics, enables the physician to better define the patient’s treatment need.

Click here to complete the new online MIDAS questionaire tool
or here to for the down-loadable  MIDAS questionnaire

What are the benefits of using MIDAS?

  • The MIDAS questionnaire promotes patient-physician communication. In addition, it raises the physician’s awareness of the impact of a patient’s migraine and the need for appropriate action.
  • Determination of the MIDAS grade allows physicians to stratify patients according to their level of migraine-related disability and, after allowing for the individual needs of each patient, to select an effective management strategy.
  • The MIDAS questionnaire allows patients and physicians to monitor a patient’s progress over time. The completion of a follow-up questionnaire 3-6 months after the consultation should show a reduction in the MIDAS score/grade over time, assuming that treatment has been effective.


Not signed in



  • Register
  • Forgotten password?

Page tools

  • Print
  • Bookmark this page

Clinical Product Summary

  • Zomig Nasal Spray
  • Zomig Rapimelt

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2008